Immune cell levels may guide breast cancer treatment in new trial
NCT ID NCT05645380
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether the number of immune cells in and around a triple-negative breast cancer tumor can help doctors personalize chemotherapy and immunotherapy. About 139 women with early-stage triple-negative breast cancer will receive standard chemotherapy drugs plus pembrolizumab (Keytruda). The goal is to see if those with high immune cell levels and good early response can have better tumor shrinkage, potentially reducing the need for more aggressive treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Carboplatin, Docetaxel, Doxorubicin, Cyclophosphamide, Pembrolizumab
What this could lead to
If successful, this could lead to a more personalized treatment approach for triple-negative breast cancer, potentially improving tumor shrinkage and reducing unnecessary chemotherapy.
What could go wrong
This is a phase 2 trial with 139 participants, so results are preliminary. The approach may not work for all patients, and chemotherapy drugs have significant side effects like fatigue, nausea, and increased infection risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The University of Kansas Cancer Center - Clinical Research Center
Fairway, Kansas, 66205, United States
-
The University of Kansas Cancer Center - Lee's Summit
Lee's Summit, Missouri, 64064, United States
-
The University of Kansas Cancer Center - Main Hospital
Kansas City, Kansas, 66160, United States
-
The University of Kansas Cancer Center - North
Kansas City, Missouri, 64154, United States
-
The University of Kansas Cancer Center - Overland Park
Overland Park, Kansas, 66210, United States
-
The University of Kansas Cancer Center - Westwood
Kansas City, Kansas, 66205, United States
-
University of Kansas Cancer Center at North Kansas City Hospital
North Kansas City, Missouri, 64116, United States